Mitsubishi Tanabe Pharma Corp operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mitsubishi Tanabe Pharma Corp with three other
companies in this sector in Japan:
Shionogi & Co Ltd
sales of 344.67 billion Japanese Yen [US$3.06 billion]
of which 100%
Eisai Company Limited
(600.05 billion Japanese Yen [US$5.32 billion]
of which 49%
was Pharmaceutical Business -Japan), and
Taisho Pharmaceutical Holdings Co Ltd
(280.09 billion Japanese Yen [US$2.48 billion]
of which 66%
During the year ended March of 2018, sales at
Mitsubishi Tanabe Pharma Corp were ¥433.86 billion (US$3.85 billion).
increase of 2.3%
versus 2017, when the company's sales were ¥423.98 billion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Mitsubishi Tanabe Pharma Corp had sales
of ¥419.18 billion.
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
113.9% in 2018, from
¥1.42 billion to ¥3.03 billion.
Mitsubishi Tanabe Pharma Corp also saw significant increases in sales in
Overseas Ethical Drug (up 70.0% to ¥38.57 billion)
General Drug (up 9.3% to ¥3.73 billion)
Not all segments of Mitsubishi Tanabe Pharma Corp experienced an increase in sales in 2018:
sales of Royalty Incomes fell 3.8% to ¥79.15 billion.
Mitsubishi Tanabe Pharma Corp also experienced decreases in sales in
Domestic Ethical Drug (down 1.5% to ¥309.37 billion)